Last updated: October 9, 2026
argenx discontinued its Phase 3 UNITY study of efgartigimod SC in Sjögren’s disease for futility on the same morning FB102 met its Phase 2 celiac endpoint, Viatris agreed to buy Pacira BioSciences for $1.65 billion in cash, and Zealand’s petrelintide passed its type 2 diabetes test.
This page covers Thursday, October 8, 2026: the argenx double readout, the Viatris and Pacira deal terms, ZUPREME-2, the Tukysa maintenance approval, the WHISTLE-PF result, the reopened IPO window, and the day’s movers, with primary sources throughout.
Why did argenx stop its Phase 3 Sjögren’s trial?
An independent data monitoring committee reviewed UNITY at a planned interim analysis and concluded the study could not meet its primary endpoint. argenx accepted the futility recommendation and discontinued the trial. Safety was consistent with efgartigimod’s known profile, and no efficacy figures were disclosed.
UNITY tested weekly subcutaneous efgartigimod, the FcRn blocker sold as Vyvgart Hytrulo, against placebo in adults with moderate to severe primary Sjögren’s disease. Enrollment required anti-Ro/SSA autoantibody positivity and meaningful systemic disease activity on stable standard of care, and the primary endpoint was the change in the clinESSDAI systemic activity score at Week 48. That endpoint choice matters: composite activity scores in heterogeneous autoimmune diseases have ended a long list of expansion programs, and Sjögren’s, with no approved targeted therapy and a wide range of organ involvement, is among the hardest proving grounds in immunology. argenx said it will run a complete analysis after database lock and share what it learns. TD Cowen had expected positive UNITY data in mid 2027, per Fierce Biotech, which is one measure of how unexpected the stop was.
| UNITY at a glance | Detail |
|---|---|
| Drug | Efgartigimod SC (Vyvgart Hytrulo), weekly |
| Design | Phase 3, randomized 1:1, double blind, placebo controlled, with open label extension |
| Population | Adults with primary Sjögren’s disease, anti-Ro/SSA positive, clinESSDAI of 6 or higher on stable standard of care |
| Primary endpoint | Change from baseline in clinESSDAI at Week 48 |
| Outcome | Discontinued for futility at interim on IDMC recommendation; no new safety signals |
What did FB102 show in celiac disease?
FB102 met the primary endpoint of its Phase 2 celiac study: a statistically significant improvement versus placebo in the villus height to crypt depth ratio at day 78, with p=0.0176, after an eight week controlled gluten challenge. Supporting histologic, inflammatory and symptom measures were consistent, and argenx will start Phase 3.
The trial (FB102-301, NCT06982963) enrolled 126 adults with confirmed celiac disease who had been symptom free on a strict gluten free diet for at least a year, randomized 2:2:1 to two intravenous FB102 dose levels or placebo, then exposed to a controlled oral gluten challenge. The readout is histology because celiac damage is histologic: gluten flattens the intestinal villi, and the Vh:Cd ratio measures whether a drug protected them. Intraepithelial lymphocyte density, the composite VCIEL score and symptoms all moved with the primary endpoint, safety matched prior studies, and effect sizes were not disclosed; detailed results go to a medical meeting. FB102 is a first in class anti CD122 antibody that blocks IL-2 and IL-15 signaling through the receptor’s shared subunit while preserving regulatory T cell function, and it holds FDA Fast Track designation in celiac disease, where no approved therapy exists beyond the diet itself. It is the asset argenx acquired with Forte Biosciences in the $2.2 billion deal agreed in July, making Thursday the fastest possible vindication of that price: the first readout after closing, positive, in the lead indication.
Why is Viatris buying Pacira BioSciences?
Viatris is paying $36.50 per share in cash, an aggregate equity value of about $1.65 billion, for Pacira’s two marketed non opioid pain products and their cash flows. The deal adds roughly $746 million in trailing revenue, closes by year end if a majority of shares tender, and is funded mostly from excess cash.
Pacira brings EXPAREL, the long acting local anesthetic used in postsurgical pain, and ZILRETTA, an extended release corticosteroid for osteoarthritis knee pain, which together produced about $746 million in revenue and about $177 million in adjusted EBITDA in the twelve months through June 2026, per the companies’ release. The pipeline adds PCRX-201, a Phase 2 gene therapy for knee osteoarthritis. The structure is a tender offer followed by a merger, both boards approved unanimously, and Viatris calls the deal immediately accretive to its guidance metrics, with minimal effect on gross leverage. The strategic logic is continuity: Viatris has been building a branded, innovative medicines business on top of its generics base, and commercial stage, patent protected pain assets with hospital call points are about the lowest risk version of that trade available. The market agreed on the price instantly. Pacira closed at $36.39, within three tenths of a percent of the offer, our arithmetic from settled closes, a spread that treats the tender as a formality.
| Deal term | Viatris / Pacira |
|---|---|
| Price | $36.50 per share, all cash |
| Equity value | About $1.65 billion |
| Structure | Tender offer, then merger for untendered shares |
| Assets | EXPAREL, ZILRETTA, PCRX-201 (Phase 2 gene therapy) |
| Pacira trailing financials | About $746 million revenue, about $177 million adjusted EBITDA (twelve months to June 30, 2026) |
| Financing | Primarily excess cash, remainder short term borrowings |
| Expected close | By end of 2026 |
What did petrelintide show in type 2 diabetes?
In the Phase 2b ZUPREME-2 trial, Zealand Pharma’s once weekly amylin analog cut body weight up to 9.2% at week 28 versus 2.0% for placebo, with gastrointestinal discontinuations of 1.9% versus 1.7% for placebo. HbA1c fell up to 0.65% from an 8.0% baseline while rising 0.23% on placebo.
The trial enrolled 220 US adults with overweight or obesity and type 2 diabetes on metformin, with or without an SGLT2 inhibitor, and compared three once weekly petrelintide doses with placebo through a 16 week escalation and maintenance to week 28, per Zealand’s release. Weight reductions spanned 7.4% to 9.2% across the arms under the efficacy estimand. The placebo adjusted HbA1c effect works out to 0.61% to 0.88% across arms, helped by the placebo arm’s rise, which William Blair called unusual, per Fierce Biotech. The comparison that will follow this program is glycemic: trade coverage noted incretin based rivals have produced HbA1c reductions of 1.3% to 2.1% in comparable populations, so petrelintide’s case in diabetes rests on tolerability and on combinations rather than on glucose control alone. Roche and Zealand have already started the Phase 3a program, with ZUPREME-3, ZUPREME-4 and ZUPREME-5 planned to enroll about 7,000 participants in total, and a Phase 2 combination of petrelintide with Roche’s incretin enicepatide is planned to begin in the second half of 2026. For context, ZUPREME-1 produced 9.8% weight loss in a population without diabetes, per Fierce Biotech’s comparison of the two trials.
| ZUPREME-2 measure | Petrelintide | Placebo |
|---|---|---|
| Body weight change, week 28 | Up to 9.2% reduction (range 7.4% to 9.2% across three doses) | 2.0% reduction |
| HbA1c change from 8.0% baseline | Up to 0.65% reduction | 0.23% increase |
| Discontinuations due to GI adverse events | 1.9% | 1.7% |
| Population | 220 adults, overweight or obesity plus type 2 diabetes, on metformin with or without an SGLT2 inhibitor | |
What did the FDA approve Tukysa for on October 7?
The FDA approved tucatinib with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable locally advanced or metastatic HER2 positive breast cancer whose disease did not progress on induction. The approval rests on HER2CLIMB-05: median progression free survival of 24.9 versus 16.3 months.
HER2CLIMB-05 enrolled 654 adults who had completed four to eight cycles of induction with trastuzumab, pertuzumab and a taxane, then randomized them to add tucatinib or placebo to the antibody maintenance backbone. The hazard ratio was 0.64 (95% CI 0.51 to 0.80, p<0.0001) by investigator assessment, overall survival was not mature at the analysis, and the label carries a boxed warning for hepatotoxicity plus warnings for diarrhea, embryo fetal toxicity and creatinine elevation, per the FDA’s approval notice. The recommended dose is 300 mg orally twice daily. The commercial picture is a sequencing fight. Pfizer’s Ibrance won a parallel first line maintenance approval in June on the PATINA trial in hormone receptor positive, HER2 positive disease, Enhertu has pushed into first line use after its late 2025 approval, and none of the maintenance datasets speak to patients coming off the newest induction regimens. Tukysa’s distinguishing asset remains the blood brain barrier: it is a small molecule with established CNS activity in HER2 positive disease, which matters in a population where brain metastases are common. Pfizer booked $463 million of Tukysa revenue in 2025, per Fierce Pharma, so the maintenance label is also a test of whether a bigger indication can revive a franchise that has run below its deal era projections.
| HER2CLIMB-05 | Tucatinib arm | Placebo arm |
|---|---|---|
| Median progression free survival | 24.9 months | 16.3 months |
| Hazard ratio | 0.64 (95% CI 0.51 to 0.80), p<0.0001 | |
| Population | 654 adults, HER2 positive unresectable or metastatic breast cancer, no progression after 4 to 8 induction cycles | |
| Key safety | Boxed warning for hepatotoxicity; diarrhea, embryo fetal toxicity, creatinine rise | |
What did Endeavor BioMedicines report in pulmonary fibrosis?
Endeavor said WHISTLE-PF, its 213 patient, 24 week Phase 2b trial of taladegib in idiopathic pulmonary fibrosis, met its primary endpoint: a statistically significant improvement in percent predicted forced vital capacity versus placebo, with key secondary imaging endpoints also hit, per its release as reported by Fierce Biotech and Endpoints.
Taladegib is an oral Hedgehog pathway inhibitor, and the claim that distinguishes this program is direction. Approved IPF drugs slow the decline of lung function; Endeavor reports improvement from baseline sustained over 24 weeks, along with significant gains versus placebo on total lung capacity and on quantitative interstitial lung disease and fibrosis imaging measures, with serious adverse events balanced between arms. The company, which is private, says it will engage the FDA on a Phase 3 strategy; detailed figures are being held for a medical meeting, so the dataset itself is not yet public, and this page will update the claim against the numbers when they print. A small 2024 Phase 2a first suggested the reversal signal, and those earlier figures should not be mixed with this trial. In a field that has absorbed repeated late stage failures, a confirmed improvement claim from a 213 patient controlled trial would reset expectations for every program in the space.
What happened in the biotech IPO market this week?
The window priced two debuts in one night. TRexBio sold 8,333,334 shares at $14.00 for roughly $116.7 million gross, with Nasdaq trading expected Friday, October 9, and Retension Pharmaceuticals priced its own IPO minutes later the same evening, per the companies’ releases as carried on the wires.
TRexBio, an autoimmune and inflammatory disease company, expects its offering to close October 13. Retension’s pricing terms had not been carried on the wire indexes we could reach as of Thursday night; the hypertension drug developer had most recently set terms for a roughly $58 million raise, per Renaissance Capital. Iambic, an AI driven oncology company, is marketing a roughly $135 million IPO, per Fierce Biotech, and Lycia filed last week. The contrast running through this column all week is the other end of the risk curve. Spyre priced a $350 million follow on at $85.00 on October 5 with closing expected on or about October 7, and as of Thursday night no closing confirmation had appeared in wire searches or the ticker’s release index, our search scope, while the stock closed at $79.90, 6.0% below the offer price. Vaxcyte’s roughly $1 billion equity and convertible pair is expected to close Friday, October 9, with 30 day greenshoes outstanding. And Caribou Biosciences, which discontinued two clinical CAR T programs this week because no financing could be found for a pivotal trial the FDA had aligned on, closed at $0.48, down 57.6% in two sessions, our arithmetic from settled closes.
| Capital event | Status as of Thursday night |
|---|---|
| TRexBio IPO | Priced: 8,333,334 shares at $14.00, about $116.7 million gross; debut expected October 9, close October 13 |
| Retension IPO | Priced the same evening; terms not yet carried on reachable wires |
| Iambic IPO | Marketing a roughly $135 million raise, per Fierce Biotech |
| Vaxcyte offerings (~$1 billion) | Close expected Friday, October 9; greenshoes on 30 day clocks |
| Spyre $350 million follow on | Priced October 5; no closing confirmation found as of October 8 night; shares 6.0% below offer |
| Caribou | No financing found at any price; wind down proceeding; stock at $0.48 |
What else moved the industry on Thursday?
A regional degrader deal, two leadership resets, a tools financing and a compliance censure filled out the day. Ono agreed to pay Biohaven $80 million upfront for Asian rights to three IgG degraders, and Boston Scientific reorganized its whole operating structure around a new chief operating officer.
Ono Pharmaceutical takes rights to BHV-1300, BHV-1310 and BHV-1320, Biohaven’s extracellular IgG degraders, in Japan, South Korea, Taiwan and ASEAN markets for $80 million upfront, a $20 million milestone and a 20% share of profits in the territories, per Fierce Biotech and Endpoints; BHV-1300 is in Phase 3 for Graves’ disease, and Biohaven calls it the first regional collaboration for the modality. Boston Scientific named cardiovascular group president Joseph Fitzgerald executive vice president and chief operating officer and will reorganize into three reportable segments on January 1, per its October 7 release, the second major medtech leadership move of the week after Stryker’s CEO succession. Matchpoint Therapeutics raised a $150 million Series B co led by Nextech Invest and Norwest to take MPT-062, an oral covalent T cell modulator, into the clinic in 2027, per BioSpace. NorthStar Medical Technologies secured up to $185 million in growth financing led by Hercules Capital to scale actinium 225 production, announced September 29 and circulating in trade coverage this week, a supply side read for every radioligand developer. The UK’s PMCPA censured CSL Seqirus over more than £700,000 in payments to a French healthcare organization made without required documentation or disclosure between 2020 and 2022, following the company’s voluntary admission, per Fierce Pharma. And Nuvig Therapeutics confirmed it halted enrollment in its Phase 2 CIDP trial of NVG-2089 on cost and timeline grounds, not safety, with its ITP study continuing, per the CEO’s statement to Fierce Biotech.
Which stocks carried a story on Thursday?
Five moves carried information beyond the tape. Pacira repriced to its offer, argenx repriced its expansion math, Caribou continued toward zero, Medtronic logged its first session after the MiniMed ratio was fixed, and Spyre drifted further below an offering that has not confirmed its close.
| Ticker | October 8 close | Move | Context |
|---|---|---|---|
| PCRX | $36.39 | +44.4% | Closed within 0.3% of the $36.50 cash offer; the market treats the tender as done |
| ARGX | $818.63 | −11.8% | UNITY futility stop outweighed the FB102 celiac win by this margin |
| CRBU | $0.48 | −22.1% | Second session since the wind down; 57.6% below the pre announcement close |
| MDT | $87.75 | +2.6% | First reaction session after the final MiniMed exchange ratio of 4.5939; offer expires at midnight October 9 |
| SYRE | $79.90 | −1.2% | 6.0% below the $85.00 offer, with the closing release still unconfirmed |
Closes are exchange settled prices; percentage moves are our arithmetic against Wednesday’s settled closes.
Frequently asked questions
Why did argenx stop the UNITY trial in Sjögren’s disease?
An independent data monitoring committee concluded at a planned interim analysis that UNITY could not meet its primary endpoint, the change in clinESSDAI systemic disease activity at Week 48, and recommended stopping for futility. argenx discontinued the study. No new safety signals were identified.
Does the UNITY stop affect Vyvgart’s approved uses?
No. Efgartigimod remains approved in generalized myasthenia gravis and, as Vyvgart Hytrulo, in CIDP. The futility stop ends the Sjögren’s expansion program, not any approved indication. The commercial question it raises is about the value of future label expansion, not current sales.
What is FB102 and how does it work?
FB102 is a first in class anti CD122 antibody. CD122 is the shared receptor subunit for IL-2 and IL-15 signaling, which sustains the immune cells that drive diseases like celiac. FB102 blocks that signaling selectively while preserving regulatory T cell function.
What did FB102 show in celiac disease?
In a 126 patient Phase 2 with an eight week gluten challenge, FB102 produced a statistically significant improvement versus placebo in the villus height to crypt depth ratio at day 78 (p=0.0176), with supporting measures consistent. argenx plans a Phase 3. Effect sizes have not yet been disclosed.
How much is Viatris paying for Pacira BioSciences?
$36.50 per share in cash, an aggregate equity value of about $1.65 billion, through a tender offer followed by a merger, funded primarily from excess cash. Both boards approved unanimously and the companies expect closing by the end of 2026.
What does Pacira sell today?
EXPAREL, a long acting local anesthetic for postsurgical pain, and ZILRETTA, an extended release corticosteroid injection for osteoarthritis knee pain. Together they generated about $746 million in revenue and about $177 million in adjusted EBITDA in the twelve months through June 2026, per the release.
What did petrelintide show in ZUPREME-2?
Weight loss of up to 9.2% at week 28 versus 2.0% for placebo in 220 adults with type 2 diabetes and overweight or obesity, with gastrointestinal discontinuations of 1.9% versus 1.7% for placebo, and HbA1c reductions of up to 0.65% from an 8.0% baseline.
How does petrelintide’s HbA1c effect compare with incretins?
Trade coverage citing William Blair put incretin rivals at 1.3% to 2.1% HbA1c reductions in comparable trials, against up to 0.65% for petrelintide, though the placebo arm’s unusual rise narrows the placebo adjusted gap to 0.61% to 0.88%. Cross trial comparisons carry the usual caveats.
What exactly did the FDA approve Tukysa for on October 7?
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of adults with unresectable locally advanced or metastatic HER2 positive breast cancer whose disease has not progressed after induction with trastuzumab, pertuzumab and a taxane, at 300 mg orally twice daily.
What is taladegib and what did WHISTLE-PF show?
Taladegib is an oral Hedgehog pathway inhibitor from the private company Endeavor BioMedicines. In the 213 patient Phase 2b WHISTLE-PF trial in idiopathic pulmonary fibrosis it met its primary endpoint, a statistically significant improvement in percent predicted forced vital capacity at 24 weeks versus placebo, per the company; detailed figures are pending.
Which biotech IPOs priced this week?
TRexBio priced 8,333,334 shares at $14.00 on October 8 for roughly $116.7 million gross, and Retension Pharmaceuticals priced its IPO the same evening. Both expect to trade on Nasdaq. Iambic is marketing a roughly $135 million raise, and Lycia has filed.
When does the Medtronic MiniMed exchange offer expire?
At midnight, end of day Friday, October 9, 2026, at the final exchange ratio of 4.5939 MiniMed shares per Medtronic share accepted. If the offer is oversubscribed, Medtronic has said it intends to exchange the remaining shares without extending. Results are likely next week.
Is Vaxcyte’s $1 billion offering closed?
Not as of Thursday night. The equity and convertible note offerings priced October 6 with closing expected October 9, and the greenshoe options run on 30 day clocks. We will report the closing from the company’s releases or filings once it occurs.
What happened to Caribou Biosciences’ stock this week?
CRBU closed Thursday at $0.48, down 22.1% on the day and 57.6% below its close before the company announced it would discontinue both clinical CAR T programs and pursue strategic alternatives. The strategic review, with Wedbush advising, has no stated timeline.
Sources
Primary sources (October 7 to 8, 2026): argenx press releases on the UNITY discontinuation and the FB102 celiac Phase 2 topline (October 8); Viatris and Pacira joint press release, filed as an 8-K exhibit with the SEC (October 8); Zealand Pharma Company Announcement No. 54/2026 on ZUPREME-2 (October 7); FDA approval notice for tucatinib with trastuzumab and pertuzumab (October 7); Boston Scientific press release, 8-K exhibit (October 7); TRexBio IPO pricing release (October 8); Medtronic final exchange ratio release (October 7); Endeavor BioMedicines WHISTLE-PF release via Business Wire (October 8, as cited by trade coverage).
Trade coverage (attributed where figures rely on it): Fierce Biotech (argenx readouts, ZUPREME-2 analyst context, WHISTLE-PF, Ono and Biohaven terms, Iambic, Boston lab vacancy); Fierce Pharma (Tukysa approval context and revenue, CSL Seqirus and the PMCPA case record); Endpoints News (Thursday headline corroboration); BioSpace (Matchpoint Series B); Renaissance Capital (Retension terms); MedTech Dive (medtech coverage).
Market data: exchange settled closing prices for October 8, 2026; percentage moves are our own arithmetic against October 7 settled closes.
Related coverage
- PhRMA sued to block Medicare’s GLOBE model as Caribou halted both CAR T programs (October 8)
- ArriVent’s firmonertinib missed in first line exon 20 lung cancer as Vaxcyte raised $1 billion (October 7)
- Vaxcyte’s VAX-31 met all primary endpoints in its pivotal adult Phase 3 (October 6)
- Novartis paid $575 million upfront for Abogen’s mRNA T cell engager (October 5)
- Lilly’s EloraTZP cut weight 23.3% in Phase 2 diabetes and obesity data (October 1)
